Tech Pioneer Creates Personalised Cancer Vaccine for Dog Using AI
A Sydney-based technology entrepreneur has achieved a remarkable medical breakthrough by developing a personalised cancer vaccine for his beloved dog, an innovation that leading experts believe could significantly influence the future of human oncology. Paul Conyngham, a dedicated tech expert, adopted his cherished companion Rosie, an eight-year-old Staffy-Shar Pei crossbreed, back in 2019, forming an unbreakable bond.
Diagnosis and Initial Treatment
In 2024, Rosie was diagnosed with mast cell cancer, the most prevalent form of skin cancer found in dogs, which typically manifests as lumps, nodules, or masses on the skin. Large tumours began to appear on one of her back legs, prompting immediate concern. Mr Conyngham invested thousands of dollars in veterinary chemotherapy treatments, which succeeded in slowing the spread of the tumours but unfortunately failed to reduce their size, leaving Rosie's condition precarious.
Innovative Approach with ChatGPT
Determined to find a solution, Mr Conyngham turned to artificial intelligence, specifically ChatGPT, to explore potential cures for the cancer. He utilised the technology to sequence Rosie's DNA and design a world-first custom mRNA vaccine tailored specifically for her condition. "We took her tumour, sequenced the DNA, we converted it from tissue to data, and we used that to find the problem in her DNA and then develop a cure based off that," Mr Conyngham explained during an interview on the Today Show. "ChatGPT assisted throughout that entire process."
Collaboration with Scientific Experts
Following the initial design, Mr Conyngham contacted Dr Páll Thordarson, the director of the prestigious UNSW RNA Institute, who used the provided data to create the groundbreaking vaccine. Dr Thordarson, who has extensive experience with mRNA technology, expressed initial concerns about the timeline but was impressed by the rapid progress. "Once we had the sequence that Paul designed, it was less than two months until we handed it over to Paul, to the vet," he noted.
Remarkable Results and Recovery
The vaccine yielded astonishing results within approximately one month, shrinking Rosie's tumour by an impressive 75 per cent to date. Mr Conyngham observed a dramatic improvement in her mobility; whereas she was struggling to move in December, by January she was energetically jumping over fences to chase rabbits. "I think it's added considerable life and healthspan to Rosie," he remarked, highlighting the vaccine's transformative impact.
Implications for Human Medicine
Dr Thordarson emphasised that this pioneering vaccine "absolutely" could be adapted to treat human cancer patients in the future. He pointed out that while companies like Moderna are already working on personalised cancer vaccines, this case demonstrates local capability and broader applications. "We can actually do this here, we don't have to necessarily rely on foreign companies to help us do this," he stated. "That means we can democratise this technology in Australia. And we can also use it for other diseases, neurological diseases, for instance."
Ongoing Research and Personal Motivation
Currently, Mr Conyngham and Dr Thordarson are sequencing a tumour that did not respond to the vaccine to investigate its resistance, aiming to refine the treatment further. When asked about his motivation for investing so much time and resources, Mr Conyngham spoke passionately about his bond with Rosie. "Rosie is my best mate," he shared. "She's been with me through really tough times, through a breakup, through hard business deals and walks in the forest. So when she was handed this sentence, I felt I had to do my part for her as well."
